HABA Laboratories, Inc. (4925) AI Stock Analysis

• Market Cap: ¥6.47B
• Dividend Yield: 2.35%
• Average Volume (3M): 1.53K
• Price to Earnings (P/E): 10.1
• Beta (1Y): 0.26
• Revenue Growth: -2.13%
• EPS Growth: N/A
• Country: JP
• Employees: 631
• Sector: Consumer Defensive
• Sector Strength: 57
• Industry: Household & Personal Products
• EPS (TTM): 10.87
• Shares Outstanding: 3,935,000
• 10 Day Avg. Volume: 1,580
• 30 Day Avg. Volume: 1,526
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,780.00
• Price Target Upside: 3.97% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 63 Neutral
• Price Target: ¥1,780.00 ▲(3.97% Upside)

HABA Laboratories' overall stock score is driven by a strong valuation due to a low P/E ratio and attractive dividend yield. However, financial performance is mixed, with strong balance sheet stability but challenges in revenue growth and profitability. Technical analysis indicates a neutral to slightly bearish trend, with potential overbought conditions. The absence of earnings call data and corporate events limits additional insights.

HABA Laboratories, Inc. Business Overview & Revenue Model

Company Description

HABA Laboratories, Inc. (4925) is a Japanese company that specializes in the development, manufacturing, and sale of cosmetics and skincare products. The company is known for its commitment to using additive-free ingredients, catering to customers who prioritize safety and quality in their beauty products. HABA Laboratories focuses on providing high-quality skincare solutions and has established a strong presence in the Japanese market, with a growing international footprint.

How the Company Makes Money

HABA Laboratories, Inc. generates revenue primarily through the sale of its skincare and cosmetic products. The company's key revenue streams include direct sales through its retail stores and online platforms, as well as distribution through third-party retailers and partners. HABA Laboratories leverages its brand reputation for safety and quality to attract and retain a loyal customer base. The company also engages in marketing and promotional activities to expand its market reach and increase sales. Strategic partnerships with retailers and distributors help HABA Laboratories to extend its product availability and enhance its earnings potential.

HABA Laboratories, Inc. Financial Statement Overview

Summary

HABA Laboratories shows a mixed financial picture. Revenue declines and inconsistent profitability challenge the income statement, while the balance sheet remains strong with low leverage and solid equity. Improving cash flow generation is a positive sign, though historical volatility presents challenges. The company demonstrates resilience in financial stability but needs to address profitability and growth concerns.

Income Statement

HABA Laboratories has faced challenges with revenue growth, showing an overall declining trend from the 2020 peak. The gross profit margin remains robust, suggesting efficient cost management, but net income has fluctuated significantly, impacting net profit margins negatively in recent years. The EBIT and EBITDA margins have been erratic, reflecting operational challenges and inconsistent profitability.

Balance Sheet

The balance sheet shows strong equity with a favorable equity ratio, indicating financial stability. The debt-to-equity ratio is low, reducing leverage risks. However, the return on equity is unstable due to fluctuating net income. Overall, the company maintains a solid asset base with a strong equity cushion.

Cash Flow

Cash flow analysis reveals improving operating cash flow in the most recent period, which is a positive sign. Yet, the company has struggled with free cash flow growth, and previous periods showed volatility. The operating cash flow to net income ratio indicates better cash generation relative to profits recently, but historical instability remains a concern.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	12.06B	12.32B	12.04B	12.91B	14.31B
Gross Profit	7.99B	8.03B	8.17B	8.79B	10.20B
EBITDA	811.56M	-1.31B	17.05M	448.30M	960.14M
Net Income	576.57M	-2.12B	-707.87M	-269.03M	216.42M
Balance Sheet
Total Assets	12.34B	12.43B	14.66B	15.69B	17.44B
Cash, Cash Equivalents and Short-Term Investments	4.74B	3.96B	4.82B	5.65B	5.66B
Total Debt	1.82B	2.36B	2.03B	2.56B	3.92B
Total Liabilities	3.42B	3.92B	3.88B	4.05B	5.40B
Stockholders Equity	8.93B	8.51B	10.77B	11.64B	12.04B
Cash Flow
Free Cash Flow	1.48B	-1.02B	-232.69M	1.53B	-346.95M
Operating Cash Flow	1.62B	-587.92M	55.96M	1.71B	534.71M
Investing Cash Flow	-147.18M	-441.79M	-214.40M	-216.49M	-925.08M
Financing Cash Flow	-689.49M	171.06M	-676.32M	-1.51B	825.38M

HABA Laboratories, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1712.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4925, the sentiment is Positive. The current price of 1712 is above the 20-day moving average (MA) of 1663.50, above the 50-day MA of 1673.02, and above the 200-day MA of 1703.25, indicating a bullish trend. The MACD of 10.25 indicates Negative momentum. The RSI at 66.61 is Neutral, neither overbought nor oversold. The STOCH value of 86.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4925.

HABA Laboratories, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4932	80 Outperform	¥11.55B	22.85		5.72%	12.45%	-3.65%
4925	63 Neutral	¥6.47B	10.12		2.35%	-2.13%	―
Sector *	63 Neutral	$20.97B	14.57	-8.07%	3.14%	2.79%	-9.97%
4936	56 Neutral	¥10.61B	51.72		2.25%	4.75%	-83.63%
4929	55 Neutral	¥6.09B	157.89		1.57%	-9.81%	―
4934	51 Neutral	¥7.53B	10.36		―	-17.95%	―
4926	45 Neutral	¥5.11B	20.26		1.68%	7.21%	―